Deutsche Bank (ETR:DBKGn) initiated coverage on Harmony Biosciences Holdings Inc. (NASDAQ: NASDAQ:HRMY), assigning a Buy rating and setting a price target of $55. The firm's analysts highlighted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback